Zevra Therapeutics (ZVRA) Operating Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) posted Operating Margin of 143.97% for Q1 2026, up 428.12% on a QoQ basis from 27.26% in Q4 2025, and up 17025.0% year-over-year from N/an in Q1 2025.
Zevra Therapeutics (ZVRA) Operating Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics' Operating Margin history runs 8 years deep, the most recent figure standing at 143.97% for Q1 2026.
- Quarterly Operating Margin rose 17025.0% year-over-year to 143.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.44% (up 17301.0% YoY) and the FY2025 annual result came in at 59.12%, up 30935.0% from the prior year.
- Operating Margin was 143.97% for Q1 2026 at Zevra Therapeutics, up from 27.26% in the prior quarter.
- Across five years, Operating Margin topped out at 143.97% in Q1 2026 and bottomed at 1978.19% in Q2 2022.
- A 5-year average of 370.34% and a median of 257.67% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin sank 202686 bps — and 2023, when it surged 190438 bps.
- Zevra Therapeutics' Operating Margin stood at 460.58% in 2022, then surged by 75 bps to 117.31% in 2023, then retreated by 9 bps to 128.34% in 2024, then surged by 121 bps to 27.26% in 2025, then surged by 428 bps to 143.97% in 2026.
- Business Quant data shows ZVRA's Operating Margin at 143.97% in Q1 2026, 27.26% in Q4 2025, and 15.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 143.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.97% |
| Dec 31, 2025 | 27.26% |
| Sep 30, 2025 | 15.90% |
| Jun 30, 2025 | -274.48% |
| Mar 31, 2025 | -26.28% |
| Dec 31, 2024 | -128.34% |
| Sep 30, 2024 | -739.00% |
| Jun 30, 2024 | -540.80% |
| Mar 31, 2024 | -598.13% |
| Dec 31, 2023 | -117.31% |
| Sep 30, 2023 | -530.71% |
| Jun 30, 2023 | -73.81% |
| Mar 31, 2023 | -404.00% |
| Dec 31, 2022 | -460.58% |
| Sep 30, 2022 | -240.86% |
| Jun 30, 2022 | -1,978.19% |
| Dec 31, 2021 | -110.07% |
| Sep 30, 2021 | -113.08% |
| Jun 30, 2021 | 48.67% |
| Mar 31, 2021 | 57.44% |